List of Excipients in Branded Drug VISUDYNE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	VISUDYNE	verteporfin for injection	0187-5600	ASCORBYL PALMITATE
Bausch Health US LLC	VISUDYNE	verteporfin for injection	0187-5600	BUTYLATED HYDROXYTOLUENE
Bausch Health US LLC	VISUDYNE	verteporfin for injection	0187-5600	LACTOSE

VISUDYNE Excipient Strategy, Formulation Patents, Generic Entry and Commercial Opportunities

Last updated: September 6, 2026

VISUDYNE is a lyophilized liposomal verteporfin injectable used with nonthermal laser activation for selected ophthalmic vascular disorders. Its commercial formulation depends on phospholipid excipients, lactose, aseptic manufacturing, lyophilization, light protection and tightly controlled reconstitution. The most attractive excipient opportunities are in pharmaceutical-grade phospholipids, lipid oxidation control, sterile lipid dispersion technology, vial-and-closure systems, and improved ready-to-use or lower-waste presentations.

The product has no biosimilar pathway because verteporfin is a small-molecule drug. Generic competition would likely require an abbreviated new drug application or, for materially different delivery systems, a 505(b)(2) application. The formulation remains technically differentiated even though the original product patents and regulatory exclusivities are mature.

What is VISUDYNE and how is it formulated?

VISUDYNE contains verteporfin, a benzoporphyrin derivative used as a photosensitizer. It is supplied as a sterile, lyophilized powder in a single-dose vial. The reconstituted product is diluted before intravenous infusion and then activated with a 689-nm laser at the treatment site [1].

The formulation uses a lipid-based delivery system rather than a conventional aqueous solution. Public product information identifies phospholipid excipients and lactose as inactive ingredients. The phospholipids form the carrier structure that improves dispersion of the highly hydrophobic verteporfin compound in an injectable medium [1, 2].

Formulation element	Function in VISUDYNE	Commercial relevance
Verteporfin	Photosensitizing active ingredient	Requires protection from light and control of aggregation
Phospholipid carrier system	Solubilizes and disperses verteporfin	Main excipient differentiation and sourcing opportunity
Egg-derived phospholipid	Liposome formation and membrane structure	Creates animal-origin, supply-chain and consistency considerations
Synthetic phospholipid	Controls lipid composition and physical properties	Opportunity for high-purity synthetic alternatives
Lactose	Bulking and lyophilization support	Affects cake structure, reconstitution and vial fill performance
Nitrogen or controlled-headspace packaging	Limits oxidative degradation	Relevant to stability and container-closure design
Light-protective packaging	Protects verteporfin from photodegradation	Necessary across manufacturing, distribution and clinic handling

The exact quantitative composition should be taken from the current approved prescribing information and chemistry, manufacturing and controls records. Public labels consistently identify the lipid and lactose excipient classes, but commercial development requires confirmation of grade, source, residual solvents, peroxide limits, particle-size distribution and lipid-to-drug ratio.

What excipients protect the performance of VISUDYNE?

The phospholipid system is the critical functional excipient platform. Verteporfin has limited water solubility, and uncontrolled aggregation could affect infusion behavior, tissue distribution, photodynamic activity and safety.

Phospholipid quality

The key specifications are likely to include:

• Chemical identity and acyl-chain composition
• Purity and related lipid impurities
• Residual solvents
• Peroxide and hydroperoxide content
• Water content
• Phase-transition behavior
• Particle-size distribution after reconstitution
• Sterility and bacterial endotoxin
• Oxidative and hydrolytic stability

Egg-derived phospholipids can provide established liposome performance but introduce variability associated with biological sourcing. Synthetic phospholipids offer tighter lot control and may support a more defensible supply strategy, although they can alter liposome size, encapsulation behavior and reconstitution performance.

Potential commercial suppliers include specialist lipid manufacturers such as Avanti Polar Lipids, Croda Pharma, Nippon Fine Chemical, Lipoid and Cayman Chemical. Supplier selection would depend on injectable-grade documentation, not catalog availability.

Lactose and lyophilization

Lactose acts primarily as a bulking and structural excipient. The relevant attributes are particle size, water content, reducing-sugar impurities, endotoxin level and compatibility with the lipid system during freezing and drying.

A generic developer could not treat lactose substitution as a routine formulation change. Trehalose, sucrose, mannitol or glycine could produce different cake morphology, residual moisture, reconstitution time and lipid-drug interactions. Each alternative would require comparative characterization and likely a new stability package.

Oxidation control

Phospholipids are vulnerable to oxidation. Oxidative degradation can change liposome permeability, increase impurities and affect verteporfin loading. Commercial opportunities exist in:

• Low-peroxide phospholipid supply
• Antioxidant-compatible lipid systems
• Nitrogen-purged vial filling
• Low-oxygen lyophilization cycles
• Oxygen-scavenging secondary packaging
• Light-resistant vial labels, cartons and transfer systems

Direct addition of an antioxidant would require careful assessment. Antioxidants can change the photochemical profile, impurity pattern and injectable safety profile.

What manufacturing barriers affect VISUDYNE generic entry?

VISUDYNE is a complex sterile injectable, even though its active ingredient is a small molecule. The principal technical barriers are formulation reproducibility and control of the reconstituted product.

A prospective generic manufacturer would need to demonstrate:

1. Comparable active-ingredient content and impurity profile.
2. Comparable liposome size and distribution.
3. Comparable drug association or encapsulation behavior.
4. Comparable reconstitution time.
5. Comparable appearance, pH and osmolality.
6. Comparable stability after reconstitution and dilution.
7. Comparable light sensitivity.
8. Sterility, endotoxin and particulate compliance.
9. Consistent performance across commercial-scale lyophilization batches.

The product is administered intravenously and used in a specialized ophthalmic procedure. That creates a narrower purchasing base than for routine hospital generics. Hospitals and retina practices may prioritize reliable supply, rapid reconstitution and predictable treatment scheduling over a small unit-price reduction.

What patent protection covers VISUDYNE?

VISUDYNE’s original patent and regulatory exclusivity period is mature. The product was approved by the FDA in 2000 for age-related macular degeneration and later received additional ophthalmic indications [1, 3].

The commercially relevant protection categories are:

Protection category	VISUDYNE position
Active-ingredient patent	Original protection is mature
Liposomal formulation patent	Original product-era protection is mature or near the end of ordinary commercial relevance
Method-of-use patents	Some historical protection may have covered photodynamic treatment protocols or disease indications
Manufacturing patents	Potentially relevant to specific lipid-processing or lyophilization methods
Orange Book-listed patents	Must be checked against the current FDA listing for NDA 021119
Regulatory exclusivity	Original approval exclusivity has expired
Biosimilar exclusivity	Not applicable to verteporfin
Pediatric exclusivity	No broadly recognized current exclusivity barrier is identified in the public product record

The principal remaining barriers are therefore technical, regulatory and commercial rather than a long remaining basic patent term. A formulation patent could still matter if it covers a narrow lipid ratio, particle-size range, manufacturing process or stability profile. Such a patent would not necessarily block all generic versions, but it could narrow the design space.

When does VISUDYNE lose exclusivity?

VISUDYNE’s core market exclusivity has already expired. The FDA approved the product in 2000, and the original statutory exclusivity periods no longer control generic timing [1, 3].

The relevant current question is not when the original product loses exclusivity. It is whether a new manufacturer can obtain approval for a technically comparable sterile liposomal injectable and whether any unexpired, enforceable formulation or method patent remains listed or asserted.

Orange Book status

FDA Orange Book status is the controlling source for listed patents and approved exclusivity associated with NDA 021119. A prospective entrant should review:

• Current patent listings for NDA 021119
• Patent-use codes
• Delisting history
• Any pediatric-exclusivity codes
• Whether the reference product is eligible for an ANDA pathway
• FDA product-specific guidance, if available

No biosimilar reference-product designation applies because VISUDYNE is not a biologic.

Which companies are challenging VISUDYNE?

Publicly visible competition has historically been limited. The principal commercial risk comes from a future generic injectable manufacturer rather than a biosimilar sponsor.

Potential entrant profiles include:

• Injectable-generic companies with sterile lyophilization capacity
• Liposome specialists
• Contract development and manufacturing organizations
• Ophthalmic companies seeking a photodynamic therapy platform
• Specialty-pharma companies targeting retina clinics

An ANDA applicant would likely assess whether the reference product’s liposome characteristics can be matched using publicly available information. A 505(b)(2) sponsor could pursue a differentiated lipid composition, improved reconstitution format or alternative presentation, but that path would carry additional clinical and regulatory requirements.

What generic entry risks exist for VISUDYNE?

The most plausible launch scenarios are:

Scenario	Product profile	Commercial impact
Direct generic	Lyophilized verteporfin liposomal injectable	Highest substitution potential
Formulation-improved generic	Faster reconstitution or improved stability	Could command a premium over a basic generic
505(b)(2) product	Modified lipid system or presentation	Potentially differentiated, with greater development burden
Clinic-oriented presentation	Reduced waste, simpler preparation or unit-dose workflow	Attractive for low-volume retina centers
Compounded alternative	Not equivalent to FDA-approved product	Regulatory and quality limitations make it a weaker substitute

The main generic launch risks are formulation mismatch, inadequate stability after reconstitution, lipid oxidation, particulate formation and difficulty demonstrating pharmaceutical equivalence. Manufacturing scale is another barrier because demand is specialized and batch sizes may be relatively small.

What formulation improvements could create commercial opportunities?

Ready-to-use or ready-to-dilute presentation

A liquid formulation could reduce reconstitution steps and preparation errors. Its main obstacle is long-term stability. Verteporfin and phospholipids must remain stable under refrigerated or room-temperature conditions without aggregation or potency loss.

Improved lyophilized cake

A redesigned cake could shorten reconstitution time, reduce foaming and improve recovery from the vial. Excipient options include alternative sugars, polyols or amino acids, but each would require compatibility and stability testing.

Lower-waste vial configuration

VISUDYNE is used according to patient body surface area and treatment protocol. A vial configuration that reduces residual product could improve pharmacy economics. Smaller vial strengths, however, could increase manufacturing and packaging costs.

Synthetic, non-animal lipid system

Replacing egg-derived lipid with a fully synthetic system could improve source control and reduce biological raw-material variability. The product would still need to demonstrate equivalent performance, including liposome structure and clinical photodynamic behavior.

Light-protective administration system

Verteporfin is light-sensitive. Improved secondary packaging, amber syringes, opaque tubing or integrated light-protection kits could reduce handling risk. These products may be sold as ancillary systems even without changing the drug formulation.

Long-term supply agreements

Pharmaceutical-grade phospholipid suppliers can pursue multi-year contracts with generic developers and specialty manufacturers. The commercial value lies in validated grade continuity, low peroxide specifications, change-control support and regulatory documentation.

How strong is the VISUDYNE patent estate?

The estate is commercially weaker than a recently launched drug’s estate because the active ingredient, original product and principal regulatory exclusivities are mature. Its residual strength depends on the scope and enforceability of any later formulation, manufacturing or use patents.

A practical strength assessment is:

Estate component	Relative strength
Verteporfin composition	Low remaining blocking value
Original liposomal formulation	Low to moderate, depending on claim survival
Specific lipid ratios	Moderate if claims remain enforceable and technically narrow
Lyophilization process	Moderate, but often design-aroundable
Treatment methods	Variable and dependent on indication and claim scope
Trade secrets and know-how	Potentially meaningful for scale-up and stability
Supplier control	Moderate commercial barrier, not a statutory exclusivity right

The strongest defensible advantage may be know-how rather than patent term. A manufacturer with validated lipid sourcing, aseptic processing, low-oxygen filling and reproducible reconstitution may have a practical lead over a nominally equivalent competitor.

What is the commercial exposure to generic competition?

VISUDYNE addresses a specialized retina market. Its revenue exposure depends on the number of treated patients, reimbursement, availability of alternative anti-VEGF therapy and the continued use of photodynamic therapy in selected disease subgroups.

Generic entry could produce:

• Price erosion in hospital and specialty-pharmacy channels
• Greater use in cost-sensitive markets
• Lower treatment cost for combination regimens
• Increased demand for smaller or lower-waste presentations
• Pressure on the branded product’s distribution and service model

The branded manufacturer can defend share through reliable supply, validated preparation support, clinic education, bundled laser-procedure services and differentiated packaging. Those measures do not restore patent exclusivity, but they can reduce switching friction.

How does VISUDYNE compare with competing ophthalmic therapies?

VISUDYNE differs from anti-VEGF products because it is a photosensitizer activated by an external laser rather than a biologic injected into the eye.

Product category	Active agent	Administration	Excipient opportunity	Competitive issue
VISUDYNE	Verteporfin	Intravenous infusion plus laser	Phospholipid liposome and lyophilization	Specialized photodynamic workflow
Anti-VEGF biologics	Ranibizumab, aflibercept and others	Intravitreal injection	Protein stabilizers, surfactants and buffers	Stronger biologic and biosimilar competition
Photodynamic alternatives	Disease- and region-specific agents	Varies	Delivery-system dependent	Smaller clinical and commercial base

VISUDYNE’s formulation opportunity is more focused on injectable lipid technology and clinic workflow than on high-volume excipient consumption.

Key Takeaways

• VISUDYNE is a lyophilized liposomal verteporfin injection whose critical excipients are phospholipids and lactose.
• Pharmaceutical-grade lipid purity, peroxide control, oxygen management and lyophilization are central commercial differentiators.
• Core patent and regulatory exclusivity are mature; the main barriers are technical reproducibility, sterile manufacturing and specialized ophthalmic distribution.
• No biosimilar pathway applies. Generic entry would most likely use an ANDA, while materially modified products could pursue a 505(b)(2) route.
• The most promising excipient opportunities are synthetic phospholipids, low-peroxide lipid supply, improved lyophilization systems, ready-to-use presentations and light-protective administration components.
• A generic developer’s highest risks are liposome comparability, reconstitution performance, oxidative stability and commercial scale.
• The current Orange Book record for NDA 021119 should be reviewed before any launch, licensing or freedom-to-operate decision.

FAQs

Can VISUDYNE use a different phospholipid system?

Yes, but a substituted phospholipid system would require comparative formulation, stability and pharmaceutical-equivalence work. Changes in lipid chain length, saturation or source can alter particle size, drug association and reconstitution.

Is VISUDYNE eligible for a biosimilar application?

No. Verteporfin is a small-molecule active ingredient, so a biosimilar application under the Public Health Service Act is not the applicable pathway.

Could a trehalose-based VISUDYNE formulation be commercialized?

Potentially. Trehalose could replace or supplement lactose as a lyophilization excipient, but the sponsor would need to establish equivalent cake structure, residual moisture, reconstitution, stability and product performance.

What is the most valuable excipient IP opportunity around VISUDYNE?

The strongest opportunities are likely to involve narrow, validated combinations of lipid composition, oxidation control, lyophilization and reconstitution performance. Broad claims covering phospholipids or lactose alone would provide limited differentiation.

Would a ready-to-use VISUDYNE product have commercial value?

Yes, if it achieved adequate shelf life and maintained liposome integrity. The value would come from reducing pharmacy preparation time, product loss, handling errors and light-exposure risk.

References

1. U.S. Food and Drug Administration. (2023). Visudyne (verteporfin for injection) prescribing information.
2. National Library of Medicine. (2024). Visudyne-verteporfin kit: DailyMed drug label.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2018). Drug products, including biological products, that contain nanomaterials: Guidance for industry.
5. European Medicines Agency. (2000). Visudyne: EPAR scientific discussion and product information.